MARKET

AYLA

AYLA

Ayala Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.65
+0.03
+0.26%
Closed 16:00 09/21 EDT
OPEN
11.63
PREV CLOSE
11.62
HIGH
12.57
LOW
11.63
VOLUME
4.28K
TURNOVER
--
52 WEEK HIGH
28.68
52 WEEK LOW
7.74
MARKET CAP
154.28M
P/E (TTM)
-4.1338
1D
5D
1M
3M
1Y
5Y
56 Biggest Movers From Yesterday
   
Benzinga · 4d ago
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
Benzinga · 5d ago
BRIEF-Ayala Pharmaceuticals Presents Early Clinical Data From The Ongoing Phase 2 Trial Of Al101 In adenoid cystic carcinoma
reuters.com · 5d ago
Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate - AL101 was well tolerated with manageable side effe...
GlobeNewswire · 5d ago
Ayala Says Phase 2 Trial Shows AL101 Demonstrates 'Meaningful' Clinical Activity in Adenoid Cystic Carcinoma
MT Newswires · 5d ago
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare an...
GlobeNewswire · 09/02 12:00
BRIEF-Ayala Pharma To Present Clinical Data From Ongoing Phase 2 Accuracy Trial And New Preclinical Results From Combination Study Of AL101 At The European Society For Medical Oncology Virtual Congress 2021
reuters.com · 09/01 12:28
Ayala Pharma Highlights Upcoming ePoster Presentations At European Society For Medical Oncology Congress Sept. 16-21, 2021
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced
Benzinga · 09/01 12:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYLA. Analyze the recent business situations of Ayala Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYLA stock price target is 22.33 with a high estimate of 29.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 2.85M
% Owned: 21.54%
Shares Outstanding: 13.24M
TypeInstitutionsShares
Increased
2
57.33K
New
4
83.55K
Decreased
4
12.81K
Sold Out
3
122.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About AYLA
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.

Webull offers kinds of Ayala Pharmaceuticals Inc stock information, including NASDAQ:AYLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYLA stock methods without spending real money on the virtual paper trading platform.